Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Males or females aged 18-75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent~* Females must be non-pregnant and non-lactating, and either surgically sterile or post-menopausal~* Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), the participant or participant's non-pregnant female partner must be using a highly effective contraceptive method~* Body mass index (BMI) ≤ 35.0 kg/square meter (m\^2)~* Participant must have been diagnosed with essential hypertension for a minimum of 3 months prior to screening~* At screening, the participant must have been on a stable regimen of 2 to 3 antihypertensive medications for at least 1 month prior to screening and will be required to maintain this regimen throughout the study, using either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB), as well as 1 or 2 additional antihypertensive medications in the following categories: beta blocker, acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, nadolol, nebivolol, propranolol, pindolol, calcium channel blocker or, non-potassium sparing diuretic~Exclusion Criteria:~* Clinically significant abnormalities in medical history, screening laboratory results, or physical examination that would render the participant unsuitable for inclusion~* History of secondary hypertension (HTN)~The use of the following at time of screening and during the course of the study:~* Other medications for the treatment of HTN (e.g., clonidine, guanfacine, guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors)~* Medications that may cause hyperkalemia (e.g., cyclosporine or tacrolimus, pentamidine, trimethoprim-sulfamethoxazole, all heparins)~* Oral or SC anticoagulants (e.g., warfarin, rivaroxaban, apixaban, heparin, lovenox)~* Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or pentaerythritol)~* Phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil, avanafil)~* Potassium-sparing diuretics (e.g., eplerenone, spironolactone, amiloride, triamterene)~Unstable/underlying cardiovascular disease defined as:~* Any history of congestive heart failure (New York Heart Association \[NYHA\] class II-IV)~* Any history of previous stroke, transient ischemic attack, unstable or stable angina pectoris, or myocardial infarction prior to screening~* 12-lead electrocardiogram (ECG) corrected using Fridericia's formula (QTcF) \> 450 milliseconds (msec) in males and \> 470 msec in females at screening, or a history or evidence of long QT syndrome~* Any clinically significant active atrial or ventricular arrhythmias~* Any history of coronary bypass or percutaneous coronary intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received ISIS 757456-matching placebo, subcutaneous (SC) injection, once-weekly for 8 weeks and an additional loading dose on Day 3.
- ISIS 757456 (Type: EXPERIMENTAL): Participants received ISIS 757456 80 mg, SC injection, once-weekly for 8 weeks and an additional loading dose on Day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).